Aditxt Finalizes Ignite Proteomics Acquisition, Strengthening Oncology Focus

An announcement from Aditxt ( (ADTX) ) is now available.

On March 11, 2026, Aditxt completed the acquisition of Ignite Proteomics, LLC, a commercial-stage precision oncology company whose functional proteomics platform helps optimize cancer therapy selection by measuring protein-level activity beyond standard genomic tests. Under the deal terms, Ignite’s owners received 36,000 shares of newly designated Series A-2 Convertible Preferred Stock with an aggregate stated value of $36 million, and Ignite will operate as a subsidiary within Aditxt’s oncology initiatives.

To support the transaction, Aditxt on March 10, 2026 filed a Certificate of Designations in Delaware creating 36,000 Series A-2 Convertible Preferred Shares, which are immediately convertible into common stock at $2.731 per share, subject to a 9.99% ownership cap, redemption rights, no regular voting rights and defined liquidation preferences. The preferred structure, which ranks below certain existing senior preferred classes, also includes purchase rights protections and a right of first refusal over potential sales of Ignite’s business or assets while the collateral agent holds the shares.

The acquisition brings Aditxt a CLIA-certified, CAP-accredited lab platform with an established Medicare PLA reimbursement rate of about $2,200 per test, as well as ongoing clinical collaborations with leading cancer centers using Ignite’s Reverse Phase Protein Array technology for therapy selection and longitudinal monitoring. This commercial foundation positions Aditxt to tap into a portion of the roughly $14 billion global cancer profiling market, including an estimated $3 billion serviceable opportunity among patients eligible for antibody drug conjugates and other targeted treatments.

In parallel, Aditxt disclosed that completing the Ignite transaction has bolstered its balance sheet, and the company now believes it exceeds Nasdaq’s $2.5 million minimum stockholders’ equity requirement tied to a December 1, 2025 deficiency notice. Nasdaq, which granted Aditxt an extension to regain compliance by May 15, 2026, will continue to monitor the company’s metrics and could still pursue delisting if future periodic reports do not confirm sustained compliance.

More about Aditxt

Aditxt, Inc. is a Nasdaq-listed social innovation platform focused on accelerating promising health innovations across autoimmunity, cancer and early disease detection, infectious diseases and women’s health. The company operates through an ecosystem of research institutions and industry partners, using a multi-program model to drive disruptive growth and address significant societal healthcare challenges.

Average Trading Volume: 284,790

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.5M

Find detailed analytics on ADTX stock on TipRanks’ Stock Analysis page.